Send to

Choose Destination
Cancer Radiother. 2013 Jun;17(3):183-90. doi: 10.1016/j.canrad.2012.12.006. Epub 2013 Mar 15.

[Prospective monocentric study of the toxicity and the efficacy of concurrent trastuzumab and radiotherapy].

[Article in French]

Author information

Département de radiothérapie, institut Curie, 26, rue d'Ulm, 75005 Paris, France.



Prospective monocentric study of the toxicities related to concurrent administration of trastuzumab to breast radiotherapy.


One hundred and seventy-three patients were treated between June 2003 and March 2009 by concurrent trastuzumab with normofractionated radiotherapy. Trastuzumab was delivered every 3 weeks (8mg/kg in the first infusion then 6mg/kg) during a median time of 12 months (2-62). Left ventricular ejection fraction was assessed by echocardiography or cardiac scintigraphy at baseline, before and after radiotherapy, every 3 months for 1 year and annually. A left ventricular ejection fraction strictly lower than 55% was considered as altered. All toxicities were evaluated using Common Terminology Criteria for Adverse Effects version 3.0.


Median follow-up was 52 months (17-88). Median age was 52 years (25-83). One hundred and thirty-four patients (77.5%) received radiotherapy to the internal mammary chain. Acute grade 1, 2 and 3 epithelitis was described in 132 (76.3%), 32 (18.5%) and six patients (3.4%), respectively. At 23 months, grade 1 and 2 fibrosis was observed in 31 and eight patients, respectively (18.8 and 4.6%). Left ventricular ejection fraction remained normal for 159 patients (91.9%) before radiotherapy. Among them, 18 (11.3%) experienced a left ventricular ejection fraction alteration, eight (5.0%) at the completion of radiotherapy. Congestive heart failure occurred in one patient (0.6%).


Toxicities related to the association of trastuzumab to breast radiotherapy were mild. Further follow-up is warranted.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center